Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Award Number: R21NS146827
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/15/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is the most common acquired chronic autoimmune neuropathy and occurs more frequently in the aged, with a peak incidence in those 70-79 years of age. How aging predisposes to peripheral nervous system (PNS) autoimmunity, however, is unclear. Early aging-associated changes include the acquisition of T cell immunosenescence, a dysfunctional, pro- inflammatory state that can lead to the spread of senescence to neighboring cell types. Our data demonstrate an increased burden of senescent T cells in patients and mice with CIDP, compared to age-matched controls. Moreover, our data suggest that peripheral nerve-infiltrating CD4+ T cells actively signal to adjacent PNS cell types, including Schwann cells, in a mouse model of CIDP. Thus, in this R21 proposal, we will test the hypothesis that senescence-associated CD4+ T cells predispose to PNS autoimmunity by inducing neighboring Schwann cells to acquire a senescent, dysfunctional state. In Aim 1, we will test how adoptive transfer of senescent T cells into an immunodeficient mouse recipients alters Schwann cell phenotype in the peripheral nerves of recipients. We will also assess whether conditioned media from senescent T cells of CIDP patients will induce senescence in a human Schwann cell line. In Aim 2, we will examine how disease protection is conferred by a senomorphic agent, ruxolitinib, in mice with CIDP and through the use of CIDP patient samples. Completion of these Aims are important steps toward a more comprehensive understanding of autoimmune mechanisms in CIDP and may point to the use of senomorphic therapies for the benefit of CIDP patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $236,250 )
2026	2026	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	5/7/2026	NEW	$236,250
														Subtotal = $236,250

Grand Total All Awards = $236,250

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Aging and T cell Senescence in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Award Number: R21NS146827

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/15/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer